Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.

Tata Mutual Fund

Tata India Pharma & Healthcare Fund-Regular Plan-Growth

★★★★★ 3rd-party

External rating

  • Source: Third-party data provider (Groww/CRISIL)
  • Original rating: 2/5, displayed as-is — TopFund does not modify third-party ratings
  • Refresh frequency: Whenever TopFund re-syncs this fund's data
  • Limitations: The provider's own rating methodology isn't disclosed here — see the provider's own site for their criteria

Full rating methodology →

TopFund Score: 66/100 · Good

How this score is calculated

  • Star rating (35%)2/5
  • 3Y CAGR (30%)19.59%
  • Expense ratio (20%)1.1%
  • AUM (15%)₹1,511 Cr

Not investment advice — an analytical read of public fund data. Methodology →

Tata Mutual Fund · Equity · Sectoral

₹38.7

+6.04 (+18.49%)

AUM: ₹1,511 Cr

NAV updated 14 days ago

Plan

Regular

Option

Growth

Risk

Very High

Expense Ratio

1.1%

Exit Load

Exit load of 0.25% if redeemed within 30 days.

Fund Manager

Rupesh Patel, Sonam Udasi

Inception

Dec 2015

Benchmark

BSE Healthcare Total Return Index

Sharpe Ratio

0.0

Std Dev (1Y)

12.14%

Historical Returns (CAGR)

Annualized trailing returns computed from NAV history — past performance only, not a guarantee of future results.

1m

+2.72%

3m

-3.21%

6m

+7.44%

1y

+6.66%

3y

+19.59%

5y

+15.19%

10y

+15.61%

since inception

+11.49%

TopFund's Take on Tata India Pharma & Healthcare Fund-Regular Plan-Growth

Tata India Pharma & Healthcare Fund-Regular Plan-Growth holds up reasonably well within the Sectoral category, currently carrying a 2-star rating. TopFund's composite Health Score, which weighs rating, 3-year CAGR, expense ratio and fund size, puts it at 66/100.

Cost: At 1.1%, the expense ratio runs 10% above the Sectoral category average of 1.0%. That gap is worth weighing against the fund's actual performance versus cheaper peers before committing to a long SIP.

Risk-adjusted performance: Over the trailing 1-year period, the fund shows a negative Sharpe ratio of 0.0 — over the past year, returns haven't kept pace with the volatility involved, even before accounting for the risk-free rate. Separately, annualised volatility of 12.14% is fairly typical for Sectoral funds.

Who should invest: This fund is best suited to investors whose goals and risk appetite align with a Equity fund. Given the Very High risk rating, this fund is not suited to short-term goals or investors who may need to exit within 2-3 years.

This is an automated, data-driven analysis based on the fund's own metrics and its category peers — not personalized investment advice. Consult a SEBI-registered advisor before investing.

Sector Allocation

Asset Allocation

Equity 99.72%
Repo 0.19%
Cash/Net Current Assets 0.09%

Frequently Asked Questions about Tata India Pharma & Healthcare Fund-Regular Plan-Growth

* Past performance is not indicative of future results. Mutual fund investments are subject to market risks.

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

No comments yet — start the discussion.